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Inﬂammatory myoﬁbroblastic tumor (IMT) of the stomach is extremely rare and its prognosis is unpredictable. We present
a 37-year-old woman with a gastric IMT. She presented epigastric pain since 2 months, anemia and weight loss associated.
Physical examination showed cutaneous pallor and mild abdominal tenderness in the epigastrium. Abdominal ultrasonography
showed a tumor near the pancreas and the CT scan revealed that the lesion was arising from the stomach. Upper endoscopy
showed a submucosal lesion of approximately 7.5cm located in the posterior wall of the gastric body such as a gastrointestinal
stromal tumor (GIST). The patient underwent a subtotal gastrectomy and Billroth I reconstruction. The histopathological and
immunohistochemical analysis revealed an IMT that originated from the gastric wall.
1.Introduction
Inﬂammatory myoﬁbroblastic tumor (IMT) is a rare neo-
plasm that occurs preferentially in children and young adults
[1]. This distinctive neoplasm is composed of myoﬁbroblas-
tic cells associated to an inﬂammatory inﬁltrate of plasma
cells, lymphocytes, and eosinophils that relapse often and
rarely metastasizes.
IMT grows as a result of a reactive inﬂammatory or post-
surgery process and commonly occurs in the lung, mesen-
tery, omentum, and retroperitoneum, but it can also be seen
in the extremities, head and neck, genitourinary tract, and
other organs [2, 3]. Nevertheless, IMT of the stomach is
extremely rare [4, 5]. At the molecular level, approximately
half of IMTs contain a clonal cytogenetic aberration that
activates the anaplastic lymphoma kinase (ALK-) receptor
tyrosine kinase gene at 2p23. Positive immunohistochemical
staining of ALK is approximately in 40–100% of IMTs,
depending on the anatomic sites [6–9]. ALK expression
distinguishesIMTfromotherdiﬀerentialdiseasesdiagnostic,
such as ﬁbromatosis, nodular fasciitis, leiomyosarcoma, and
gastrointestinal stromal tumor, which do not express ALK
[1].
Clinically, the majority of IMTs are benign but they re-
q u i r ea d e q u a t es u r g i c a lt r e a t m e n tb e c a u s ei th a sat e n d e n c y
for local recurrence [1, 10, 11].
W er e p o r tac a s eo fg a s t r i cI M Ti na na d u l tw o m a na n da
review of the literature.
2.CaseReport
A 37-year-old woman presented with epigastric pain since 2
months with weight loss associated (45pounds). She denied
other gastrointestinal symptoms and signs such as nausea,
vomiting, abnormal bowel habits, melena, or hematemesis.
She had no medical or familial history. Physical examination
showed cutaneous pallor and mild abdominal tenderness in
theepigastriumbutnopalpableabnormalabdominaltumor.
The laboratory ﬁndings, including tumor markers, were
normals, except for a normocytic, normochromic anemia
(hemoglobin: 7.7g/dL). Abdominal ultrasound showed2 Case Reports in Medicine
Figure 1: CT scan showing the lesion in the posterior wall of
stomach (arrow).
Figure 2: Endoscopic image of the submucosal lesion in the
posterior wall of the gastric body.
cholelithiasis and a lesion (6.8 × 4.8 × 7.3cm) near the
pancreas. There was no evidence of internal calciﬁcations,
connection to the pancreatic duct, or ﬂow in the color
doppler ultrasonography. However, the CT scan (Figure 1)
revealed that the lesion was arising from the posterior wall of
the stomach.
Upper digestive endoscopy revealed a submucosal,
broad-based, and protruding tumor of approximately
7.5cm, located in the posterior wall of lower gastric body
such as a gastrointestinal stromal tumor (GIST) (Figure 2).
The patient underwent subtotal gastrectomy and Bill-
roth I reconstruction. Macroscopically, the tumor measured
9.0cm × 7.0cm × 6.0cm. The external surface of a well-
encapsulated lump of soft solid tumor was smooth and
glistening but without gastric mucosal lesion. On serial
sectioning, the cut surface was characterized by several
amorphous fragments of ﬁbrous tissue. Histologically, the
tumor was composed of round and spindle-shaped myoﬁ-
broblastic cells, diﬀusely scattered inﬂammatory cells, and
many vascular structures (Figures 3 and 4). The tumor
Figure 3: (H-E, 40x): Lobular and solid tumor inﬁltrating the
muscular layer of gastric wall.
Figure 4: (H-E, 200x): Solid tumor cytologically composed of
a compact proliferation of spindle cells arranged in a fascicular
growth pattern.
cells showed positive immunoreactivity for vimentin and
anaplastic lymphoma kinase (ALK), while being negative for
c-kit, CD34, desmin, smooth muscle actin (SMA), and S-
100 (Figure 5). Ki-67 labeling index was approximately 30%.
Lymph nodes (11) found along the gastric vessels in the
omentum were all negative for tumor.
The ﬁnal diagnosis was consistent with IMT that origi-
nated from the gastric wall.
The patient had an uneventful postoperative period and
has been followed up without any recurrence.
3. Discussion
The primary inﬂammatory myoﬁbroblastic tumor (IMT) is
a very rare neoplasm in adults and the exact nature of the
disease is not yet completely understood [12]. It was once
accepted that IMT is primarily a disease of children and
young adults and commonly occurs in the lungs [13, 14].Case Reports in Medicine 3
Figure 5: (ALK-1, 200x): Positive stain for ALK protein at
immunnohistochemistry.
However, recently the authors veriﬁed that the IMT can
o c c u ri na n yo r g a no ft h eb o d ya n di na l la g e s[ 6].
ThehistologicalappearanceofagastricIMTsissimilarto
that of soft tissue IMTs. It has been debated whether IMT is
a tumor or inﬂammation, and also whether it is benign or
malignant. However, studies on cytogenetic abnormalities,
such as rearrangements of the ALK gene on chromosome
2p23, clonal chromosome abnormalities, and DNA aneu-
ploidy, and the role of oncogenic viruses in the pathogenesis
of IMT suggest that it is a real neoplasm [6, 7, 15, 16].
This entity is characterized by a myoﬁbroblastic prolif-
eration, a lymphoplasmacytic inﬁltrate distributed among
the tumor cells and a myxoid background stroma. Three
architectural patterns have been described in IMT: myxoid
hypocellular pattern, a cellular fascicular or nested pattern
with variable amounts of myxoid stroma, and a sclerotic,
hyalinizedpatternwithminimalmyxoidstroma[3,4,13,17–
21]. These patterns are often mixed in a single tumor. The
myoﬁbroblasticcellsinIMTsarespindled and/orepithelioid.
In our case, the volume of the tumor, the presence of cellular
atypia, and the high Ki-67 labeling index suggest aggressive
neoplasm.
As far as the diﬀerential diagnosis is concerned, there are
a few tumors or lesions in the stomach that must be dis-
tinguished from IMT. They include gastrointestinal stromal
tumor (GIST), inﬂammatory ﬁbroid polyp, smooth muscle
neoplasm, peripheral nerve sheath tumor, solitary ﬁbrous
tumor, ﬁbromatosis, and, rarely, the follicular dendritic cell
sarcoma [12]. GIST may show cyst formation, hemorrhage,
or necrosis, which were only occasionally seen in some
IMTs. GIST typically does not have the inﬂammatory back-
ground seen in the IMT [22, 23]. In addition, some GIST
cells have cytoplasmic vacuoles, a feature not seen in the
IMT. Immunohistochemically, GIST is typically positive for
CD117 but negative for ALK, whereas IMT shows an oppo-
site proﬁle.
Clinically, IMT presents with an abdominal mass or
cystic lesion with related compressive symptoms, such as
abdominal pain and vomiting. It was described a case that
bled spontaneously into the peritoneal cavity and developed
a hemoperitoneum [12] .K i me ta l .r e p o r t e dac a s ew i t h
peritoneal dissemination [24] and Leon et al. described
an IMT of the gastric remnant in woman with a prior
gastrectomy [25].
Most IMTs require surgery to obtain deﬁnite diagnosis
and treatment. Nevertheless, local excision is an option in
selected cases [26]. Complete resection is the preferred sur-
gical treatment, because incomplete excision has been shown
to be a risk factor for recurrence [1, 10, 11].
Recently, ALK reactivity was found to be associated with
local recurrence, but not distant metastasis, which was con-
ﬁned to ALK-negative lesions, suggesting that reactivity may
be a favorable prognostic indicator in IMTs [6]. However,
other studies did not conﬁrm such an association [8]. Dif-
ferentiation between aggressive and nonaggressive forms of
IMTremainstobefurtherclariﬁed.Aftercompleteresection,
the prognosis of IMT is generally good with a low risk of
distant metastasis [10, 11, 13].
Concluding, the main diﬃculty in the management of
IMTliesintheunpredictablepostoperativecourse.Thereare
no deﬁnitive clinical, histopathological, or genetic features to
predict recurrence or metastasis.
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